10x Genomics, Inc. (NASDAQ: TXG) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -0.17 | Insider Own | 7.37% | Shs Outstand | 126.96M | Perf Week | 2.16% |
| Market Cap | 6.00B | Forward P/E | - | EPS next Y | -0.71 | Insider Trans | -1.73% | Shs Float | 114.79M | Perf Month | 21.05% |
| Enterprise Value | 5.59B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 14.16% | Perf Quarter | 114.38% |
| Income | -22.20M | P/S | 9.39 | EPS this Y | -373.98% | Inst Trans | - | Short Ratio | 5.19 | Perf Half Y | 127.26% |
| Sales | 638.78M | P/B | 7.45 | EPS next Y | 12.19% | ROA | -2.23% | Short Interest | 16.25M | Perf YTD | 189.82% |
| Book/sh | - | P/C | 47.44 | EPS next 5Y | - | ROE | -2.86% | 52W High | 50.06 -6.10% | Perf Year | 239.83% |
| Cash/sh | - | P/FCF | 49.12 | EPS past 3/5Y | - | ROIC | -4.24% | 52W Low | 11.10 323.57% | Perf 3Y | -22.18% |
| Dividend Est. | - | EV/EBITDA | 59.94 | Sales past 3/5Y | 7.61% 16.55% | Gross Margin | 69.60% | Volatility | 6.12% 6.51% | Perf 5Y | -74.24% |
| Dividend TTM | - | EV/Sales | 8.75 | EPS Y/Y TTM | 88.82% | Oper. Margin | -6.06% | ATR (14) | 2.87 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.42 | Sales Y/Y TTM | 4.58% | Profit Margin | -3.55% | RSI (14) | 62.36 | Recom | 2.59 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.90 | EPS Q/Q | 72.22% | SMA20 | 6.17% | Beta | 2.01 | Target Price | 32.71 |
| Payout | 0.00% | Debt/Eq | 0.10 | Sales Q/Q | -2.58% | SMA50 | 29.20% | Rel Volume | 0.85 | Prev Close | 47.27 |
| Employees | 1,178 | LT Debt/Eq | 0.18 | Earnings | Aug 06 | SMA200 | 102.40% | Avg Volume | 3.14M | Price | 47.01 |
| IPO Date | Sep 12, 2019 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 63.65% 3.03% | Net Debt/EBITDA | -4.38 | Volume | 2,659,197 | Change | -0.55% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-17-26 | Reiterated | Leerink Partners | Market Perform | $40 |
| Jul-14-26 | Reiterated | Canaccord Genuity | Buy | $22 → $50 |
| Jul-09-26 | Reiterated | Morgan Stanley | Equal Weight | $22 → $37 |
| Jun-24-26 | Reiterated | Barclays | Overweight | $30 → $40 |
| May-12-26 | Reiterated | Morgan Stanley | Equal Weight | $20 → $22 |
| Apr-14-26 | Reiterated | Barclays | Overweight | $22 → $30 |
| Mar-31-26 | Upgrade | William Blair | Market Perform → Outperform | |
| Mar-02-26 | Reiterated | Stifel Nicolaus | $20 → $25 | |
| Feb-20-26 | Reiterated | UBS | Neutral | $13 → $20 |
| Feb-13-26 | Reiterated | Deutsche Bank | Hold | $16 → $17 |
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 639 | 643 | 611 | 619 | 516 | 490 | 299 | 246 | 146 | |
| Cost of Goods Sold Incl. D&A | 195 | 199 | 196 | 209 | 120 | 74 | 58 | 61 | 29 | |
| Gross Profit | 444 | 444 | 414 | 409 | 396 | 416 | 240 | 185 | 118 | |
| Selling, General and Administrative Excl. Other | 292 | 316 | 344 | 343 | 298 | 258 | 202 | 131 | 88 | |
| Research and Development | 231 | 239 | 265 | 270 | 266 | 212 | 123 | 83 | 48 | |
| Other Operating Expense | -39 | 0 | 0 | 62 | 0 | -1 | 1 | 0 | -1 | |
| Operating Income | -39 | -111 | -195 | -265 | -168 | -53 | -85 | -29 | -111 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 2 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 19 | 71 | 17 | 17 | 6 | 0 | -447 | 1 | 1 | |
| Net Income Before Taxes | -19 | -40 | -178 | -249 | -162 | -54 | -534 | -31 | -112 | |
| Income Taxes | 3 | 4 | 5 | 6 | 4 | 5 | 8 | 0 | 0 | |
| Consolidated Net Income | -21 | -44 | -183 | -255 | -166 | -58 | -543 | -31 | -112 | |
| Net Income From Continuing Operations | -21 | -44 | -183 | -255 | -166 | -58 | -543 | -31 | -112 | |
| Net Income | -21 | -44 | -183 | -255 | -166 | -58 | -543 | -31 | -112 | |
| EPS (Recurring) | -0.17 | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | -8.40 | |
| EPS (Basic, Before Extraordinaries) | -0.17 | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | -8.40 | |
| EPS (Diluted) | -0.17 | -0.35 | -1.52 | -2.18 | -1.46 | -0.53 | -5.37 | -0.80 | -8.40 | |
| EBITDA | 94 | 4 | -134 | -205 | -128 | -25 | -514 | -21 | -106 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 9.42 | 3.17 | 2.82 | 10.58 | 8.05 | 33.44 | 47.83 | 12.09 | — | |
| Gross Margin | 69.48 | 69.05 | 67.76 | 66.07 | 76.74 | 84.90 | 80.27 | 75.20 | 80.82 | |
| Operating Margin | -6.10 | -17.26 | -31.91 | -42.81 | -32.56 | -10.82 | -28.43 | -11.79 | -76.03 | |
| Net Margin | -3.29 | -6.84 | -29.95 | -41.20 | -32.17 | -11.84 | -181.61 | -12.60 | -76.71 | |
| Shares Outstanding | 128 | 125 | 120 | 117 | 114 | 110 | 101 | 39 | 13 | |
| Market Capitalization | 6,017 | 2,039 | 1,723 | 6,547 | 4,154 | 16,386 | 14,302 | 2,974 | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer | Jun 22 '26 | Sale | 34.44 | 30,000 | 1,033,267 | 1,108,380 | Jun 24 |
| SULIMAN SHEHNAAZ | Director | Jun 16 '26 | Sale | 32.63 | 5,723 | 186,756 | 31,722 | Jun 18 |
| Saxonov Serge | Chief Executive Officer | May 26 '26 | Sale | 24.71 | 10,718 | 264,833 | 1,138,380 | May 27 |
| Hindson Benjamin J. | See Remarks | May 22 '26 | Sale | 24.44 | 11,595 | 283,399 | 502,000 | May 27 |
| Saxonov Serge | Chief Executive Officer | May 22 '26 | Sale | 24.44 | 18,175 | 444,224 | 1,149,098 | May 27 |
| Taich Adam | Chief Financial Officer | May 22 '26 | Sale | 24.44 | 15,098 | 369,018 | 379,898 | May 27 |
| Saxonov Serge | Chief Executive Officer | Apr 14 '26 | Sale | 24.56 | 5,000 | 122,784 | 1,167,273 | Apr 16 |
| Saxonov Serge | Chief Executive Officer | Mar 24 '26 | Sale | 19.52 | 5,000 | 97,612 | 1,172,273 | Mar 25 |
| Saxonov Serge | Chief Executive Officer | Mar 23 '26 | Sale | 19.13 | 10,000 | 191,297 | 1,177,273 | Mar 25 |
| Saxonov Serge | Chief Executive Officer | Mar 02 '26 | Sale | 22.73 | 16,152 | 367,096 | 1,203,667 | Mar 04 |
| Teichmann Sarah A. | Director | Feb 25 '26 | Sale | 19.41 | 7,579 | 147,108 | 26,780 | Feb 27 |
| Saxonov Serge | Chief Executive Officer | Feb 23 '26 | Sale | 18.58 | 9,632 | 178,928 | 1,061,924 | Feb 25 |
| Taich Adam | Chief Financial Officer | Feb 23 '26 | Sale | 18.58 | 8,968 | 166,593 | 288,417 | Feb 25 |
| Hindson Benjamin J. | See Remarks | Feb 23 '26 | Sale | 18.58 | 7,826 | 145,379 | 424,779 | Feb 25 |
| Saxonov Serge | Chief Executive Officer | Jan 05 '26 | Option Exercise | 1.20 | 100,000 | 120,000 | 1,071,556 | Jan 07 |